News Center
Research Alliance to Fight Metabolic Diseases

On Thursday, December 28 2017, a clinical research alliance was formally ratified between the Shanghai Institute of Endocrine & Metabolic Diseases – National Clinical Research Center for Endocrine & Metabolic Diseases (SIEMD-NCRCEMD) and Shanghai Pharmaceutical Holding Co (SPH). The meeting took place at the SPH headquarters in Shanghai.

The meeting was facilitated by Mr. Liu Yanjun, VP at SPH in charge of R&D. As a result of fruitful discussions, the Framework Agreement on the Clinical Research Alliance between Shanghai Institute of Endocrine and Metabolic Diseases - National Clinical Research Center for Endocrine and Metabolic Diseases and Shanghai Pharmaceutical Holding Co., Ltd. was signed by Mr. Ningguang, academician of Chinese Academy of Engineering,  Vice-President at the Rui Jin Hospital, affiliated to Shanghai Jiao Tong University and Director at SIEMD-NCRCEMD and Mr. Cho Man, President and Executive Director at SPH. Both leaders emphasized the close research collaboration between SPH and the Rui Jin Hospital and expressed wishes for future success in turning academic and clinical research results into successful and innovative therapies. Five research projects are included in this agreement, including A Study on Microecological Drugs for Metabolic Diseases and A Clinical Study on Metabolic Diseases.

Metabolic diseases have reached epidemic levels around the world. In China, clinical obesity affects 39% of the population today, a sharp rise from 3.9% thirty years ago. Diabetes is now a major public health issue worldwide, with China ranked first for the number of diabetics (114 mm people). SIEMD cutting edge basic and clinical research at the Rui Jin Hospital, combined with SPH’s expertise in clinical applications of promising drugs will be instrumental in developing and marketing future products to control these diseases. 

 

The subject of concern
Produced By 大汉网络 大汉版通发布系统